Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunologic memory after infant priming with 10-valent pneumococcal conjugate vaccine versus Prevenar using a Pneumovax 23 booster
2006-000560-93Phase 3Completed
- Sponsor
- GSK
- Start
- May 2006
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of 23-valent pneumococcal polysaccharide vaccine, pneumococcal 7-valent conjugate vaccine and 10-valent pneumococcal conjugate vaccine in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Serotype-specific antibody response one month after Pneumovax 23 booster. Started May 2006; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccinepneumococcal 7-valent conjugate vaccine10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2006-000560-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000560-93.